


<b>Bioanalytical</b>			
5	Average cost for a single bioanalytical sample	500	800
6	Average cost for a single subject analysis for 50 tests	25,000	40,000
7	Average cost for a 30 subject analysis for 50 tests	7,50,000	12,00,000
8	Approximate cost for 25 Pilot studies (covering average number of 30 subjects in each Pilot study) in a year	$5,40,000 \times 25 = \text{Rs. } 1,35,00,000$ <b>Plus</b> $7,50,000 \times 25 = \text{Rs. } 1,87,50,000$ <b>Sub-total = Rs. 3,22,50,000</b>	$7,65,000 \times 25 = \text{Rs. } 1,91,25,000$ <b>Plus</b> $12,00,000 \times 25 = \text{Rs. } 3,00,00,000$ <b>Sub-total = Rs. 4,91,25,000</b>
9	Approximate cost for 25 Pivotal studies (covering average number of 60 subjects in each Pivotal study) in a year	$5,40,000 \times 2 \times 25 = \text{Rs. } 2,70,00,000$ <b>Plus</b> $7,50,000 \times 2 \times 25 = \text{Rs. } 3,75,00,000$ <b>Sub-total = Rs. 6,45,00,000</b>	$7,65,000 \times 2 \times 25 = \text{Rs. } 3,82,50,000$ <b>Plus</b> $12,00,000 \times 2 \times 25 = \text{Rs. } 6,00,00,000$ <b>Sub-total = Rs. 9,82,50,000</b>
10	Other Miscellaneous cost for 25 Pilot and 25 Pivotal studies (covering average	<b>Rs. 32,50,000</b>	<b>Rs. 32,50,000</b>

Skylimit Research Private Limited



Director

	number of 60 subjects in each Pivotal study) in a year @ 65000/- per study		
<b>Overall Cost</b>	Approximate cost for 50 studies (25 Pilot and 25 Pivotal) in a year	<b>Rs.10,00,00,000</b>	<b>Rs.15,06,25,000</b>

Based on the proposed Clinical Research Organization setup and the above assumptions, a notable difference is evident in the actual study subject cost compared to the vendor industry cost, representing a substantial gross profit margin of approximately 50%. The company expects to garner total 50 studies (25 Pilot and 25 Pivotal) in 1st year of the operations and the number of studies are expected to increase to 100 and 150 with 50% share of Pilot and Pivotal studies in the 2nd and 3rd year of operations.

#### **Study timelines**

The study timelines encompass various phases, namely the clinical phase, bioanalytical phase, statistical phase, and report generation.

#### **Clinical phase:**

Subject Screening: Approximately 10 days

Subject In-house: Approximately 10 days

Ambulatory Visit: Approximately 2 days


Total Duration for Clinical Phase (Normal): 22-24 days

#### **Bioanalytical phase:**

Method Development: Approximately 10 days

Method Validation: Approximately 8 days

Skylimit Research Private Limited



Director

Subject Sample Analysis: 16 days (Considering a minimum of 3 subjects each day for a 30-subject study)

**Statistical phase:**

Statistical Analysis: 2 days

**Report generation:**

Report Compilation: 15 days

**5.0 Clinical research organization set-up timelines and approvals**

The Clinical Research Organization setup spans the following durations:

1. Structural Set-Up - 4 months
2. Bed and Instrument Set-Up - 2 months    **Total: 6 months**

The entire setup, along with documentation (SOP preparation, logbook preparation, manpower recruitment, and personnel training), is anticipated to be completed within a 6-month period.

**Approvals/third-party agreements for bioanalytical laboratory**

Approvals and agreements include:

Biowaste disposal approval from the local municipal corporation

Pollution board approval for chemical and biowaste disposal.



**5.2 Plan for regulatory inspection**

Skylimit Research Private Limited

Director

- 
- DCGI approval is required, planned post-setup completion.
- Initial three months of pilot study samples to identify operational gaps and ensure SOP implementation.
- Subject to regulatory inspection upon submission of pivotal studies to regulatory agencies (e.g., USFDA, EU, Canada, WHO, ANVISA).

## ➤ **6.0 Clinical research organization layout**

The layout comprises clinical, bioanalytical, and administrative areas.

### **6.1 Clinical department:**

- 
- Screening area
- Clinical unit (recreation, dining, phlebotomy)
- Pharmacy
- Sample separation area
- Emergency care unit.

### ➤ **6.2 Bioanalytical department:**

- 
- Instrument room
- Sample preparation room
- Balance room
- Deep freezer room
- Store room
- Scientist room
- Washing area.

### ➤ **Administrative area:**

- HR and Admin
- Report writing
- Quality assurance
- Archival.

**Skyllimit Research Private Limited**

*Kumar*

**Director**



### **1. Land & Building:**

The Company has executed lease agreement on 29.01.2024 for the premises situated at Plot no. 28, Sector 155, Phase II, Noida , which is a 04 story building constructed on a plot area 1000 square meters and the entire leasable area is 32000 square feet which is sufficient for the setting up of the CRO. The monthly lease rent is Rs. 6,40,000.00 and the initial lease period is for 5 years with 5% annual increase in rent after expiry of 12 months of lease period and the lease agreement shall be automatically renewed for next 05 years after the expiry of the agreement as per the agreed terms. The proposed site of the CRO is well connected with the rest of the NOIDA and Greater Noida and easily approachable to the leading hospitals in the Delhi/NCR area. The Leased premises having 32000 square feet of carpet area is sufficient to house the 100 beds for the subjects, clinical department, statistical/archive department, administrative, bioanalytical, screening, pharmacy and other areas. The leased premises are sufficient to smoothly conduct upto 250 studies each year.

#### **Power Load and water connections :-**

The Lessor has agreed to provide a 54 KW power load in the premises and further power load can be enhanced from the power distribution companies whenever there is such requirement. The leased property is situated in the Authority notified Institutional/industrial area and there is no problem in getting the requisite power load and water connections.

#### **Installed capacity of unit:-**

The leased premises are sufficient to smoothly conduct upto 250 studies each year and after touching this milestone, the company will explore additional premises in the neighborhood.

### **Clinical research organization investment/ Total Project Cost**

The establishment of the new Clinical Research Organization involves a comprehensive setup, covering clinical, bioanalytical, and administrative areas, including instrument installation, engineering works/fittings, manpower requirements and preliminary expenses.

Skyllmit Research Private Limited



Director

**Details of Plant/Machineries/ Equipment required for the CRO**

S.No	Details of the equipment/Plant/Machinery/Item	Name of vendor/supplier/ Contractor	Invoice no. & date	Invoice value with GST INR
1	Haier make Freezer, 230V/50 Hz. Model : DW-86L828J Type Upright - 86°C ULT Freezer Capacity : 828 Litres	Care Biosystems India Pvt. Ltd Mumbai	No.- CBS/srpl/2024/01 dated 12.01.2024	46,02,000.00
2	600 bar HPLC with DAD with Openlab CDS 2.7 Workstation plus	Agilent Technologies I Pvt Ltd Block C RMZ Centinnial, Plot no 8A,8B,8C,8D Dodanukundi Industrial Area, ITPL Road Mahadevpara Post Bangalore 560048	IN-J9AB1S-124-10522553 dated 12.01.2024	56,29,001.20
3	600 bar HPLC with UV detector and OpenLab CDS 2.7 Workstation plus	Agilent Technologies I Pvt Ltd Block C RMZ Centinnial, Plot no 8A,8B,8C,8D Dodanukundi Industrial Area, ITPL Road Mahadevpara Post Bangalore 560048	IN-J9AB1S-124-10522553 Quotation Date: 12 January 2024	46,85,507.96
4	FLD single wavelength	Agilent Technologies I Pvt Ltd Block C RMZ Centinnial, Plot no 8A,8B,8C,8D Dodanukundi Industrial Area, ITPL Road	IN-J9AB1S-124-10522553 Quotation Date: 12 January 2024	11,83,419.64

Skylimit Research Private Limited



Director



		Mahadevpara Post Bangalore 560048		
5	SCIEX Triple Quad 4500 System Upgradeable to QTRAP functionality with PN 5049829 Enhanced high performance triple quadrupole LC-MS/MS mass spectrometer.- Two Numbers Plus TQ/QT Software Starter Kit - with SCIEX OS-MQ 3.3- Two Numbers Plus CABLE* POWER INDIA 10A/250V- Twenty Numbers	SCIEX India Pvt. Limited Registered office: 3rd floor, Unit # 9215, B-Wing, Art Guild House, Phoenix Market city, LBS Road, Vimersia Media technologies Pvt Limited Kurla West, Mumbai, Maharashtra 400070. Phone: 022 3026 7000.	SCIEX-Delhi/HT/Skylimi t/174282/24 dated 12.01.2024 to be imported from Singapore/Netherlands for total CIP, Delhi for USD 6,32,000.00 Plus 18% GST = USD 7,45,760.00 converted to INR @ 84.50 = Rs. 6,30,16,720.00	6,30,16,720.00
6	SCIEX Triple Quad 5500+ System QTRAP Activated- Enhanced high performance triple quadrupole LC-MS/MS mass spectrometer with activated linear ion trap- Two Numbers Plus TQ/QT Software Starter Kit - with SCIEX OS-MQ 3.3- Two Numbers	SCIEX India Pvt. Limited Registered office: 3rd floor, Unit # 9215, B-Wing, Art Guild House, Phoenix Market city, LBS Road, Vimersia Media technologies Pvt Limited Kurla West, Mumbai, Maharashtra 400070. Phone: 022 3026 7000	SCIEX-Delhi/HT/Skylimi t/174281/24 dated 12.01.2024 to be imported from Singapore/Netherlands for total CIP, Delhi for USD 7,22,200.00 Plus 18% GST = USD 8,52,196.00 converted to INR @ 84.50 = Rs. 7,20,10,562.00	7,20,10,562.00

Skyllimit Research Private Limited

*Kaas*

Director

	Plus CABLE* POWER INDIA 10A/250V- Twenty Numbers			
7	Logan Water Jacketed Automated Transdermal Diffusion Cell System(24Cell System)	SANGUINE BIO INSTRUMENTS Flat No. 103, Sai Vinayaka Residency, Road No. 2, NBR Colony, Meerpet, Saroor Nagar (M), R.R. Dist., Hyderabad	SBI/LGN/SKY/9 1324/186/2023-24 dated 11.01.2024 to be imported from Somerset County, New Jersey, USA for total CIP, Delhi for USD 2,63,740.00 Plus 18% GST = USD 3,11,213.20 converted to INR @ 84.50 = Rs. 2,62,97,515.40	2,62,97,515.40
8	Supply & Installation of Walk in Freezer Room with Ante Room as per the Annexure I A - Basis of Design ( Including 15 Rft Copper Piping for the distance between IDU & ODU) 20' W x 15'L x 8' Ht. (300 Sqft.)	BLUE COOL SOLUTIONS G-62, Ground Floor, Shagun Arcade, Near Dindoshi Bus Depot, Dr. A K Vaidya Marg, MALAD - EAST, MUMBAI - 400 097, INDIA, Mobile: +91 84549 45070	BSL/BCS/23-24/308 dated 10.01.2024	12,57,502.40
9	Bio-eVap DP Nitrogen Evaporator(Dual Press 144 Position) one set plus speX Series 144 Position	Takahe Analytical Instruments, Navi Mumbai	S000478 Dated 10.01.2024	18,23,100.00

Skylimit Research Private Limited



Director



	Solid Phase Extraction one set plus Multitube Vortexer Main Unit two sets			
10	Price for 5702 R with A-4-38 rotor incl. adaptor for 13/16 mm blood collection tubes, 2 set of 2 adaptors	Eppendorf India Private Limited Jasola Vihar, New Delhi	Email dated 16.01.2024 Qty. 5 2250000 Rs. Plus GST Extra with One year Warranty.	26,55,000.00
11	Micropipettes ( Volume range 10-100 ul, 20- 200 ul, 100-1000 ul and 500-5000 ul ) each Volume range	Eppendorf India Private Limited Jasola Vihar, New Delhi	Email dated 16.01.2024 Qty. 5 300000 Rs. Plus GST Extra with Three year warranty.	3,54,000.00
12	Multipette M4 Starter kit , 1- channel, incl. Combitips advance rack, Combitips advance assortment pack	Eppendorf India Private Limited Jasola Vihar, New Delhi	Email dated 16.01.2024 Qty.5 157 500 Rs. plus GST extra with One year warranty.	1,85,850.00
13	Techno- Commercial Offer for MEP & Interior work	ADHARSHILA POWER CORPORATION G- 200, Sector- 63, Noida (U.P)- 201307	APC/MRC/OFF ER/ 23-24/752 dated 03.01.2024 quoted price @ Rs. 2000/- per Sq Ft for 30000 sq. ft carpet area	7,08,00,000.00
14	Kirloskar 125 KVA water cooled Genset three phase	Kirloskar		33,51,200.00

Skyllimit Research Private Limited



Director

15	Interior Designs & Drawings	ARCHITECTS ATELIER H-123, Delta-2, Greater Noida. +91-9811399639	Dated 02.01.2024	53,10,000.00
16	Entris II Analytical balance and Cubis II Micro Analytical balance	SB Bio Chem	SB0123/2024/2 40124 dated 24.01.2024	29,78,320.00
17	Agilent ICPMS – 7850 • PC and Printer are included • Microwave Digestion Included • IQ/OQ included • Autosampler Included • Gases supplies are not Included	Agilent Technologies, Agilent Technologies India Pvt. Ltd. Block C, RMZ Centennial, Plot Nos. 8A, 8B, 8C & 8D, Doddanakundi Industrial Area, ITPL Road, Mahadevapura Post, Bangalore- 560048	Quotation Number: IN- J9VE24-124- 095 dated 06.02.2024	1,07,38,000.00
18	Non Agilent Product Microwave Digestion system	Agilent Technologies, Agilent Technologies India Pvt. Ltd. Block C, RMZ Centennial, Plot Nos. 8A, 8B, 8C & 8D, Doddanakundi Industrial Area, ITPL Road, Mahadevapura Post, Bangalore- 560048	Quotation Number: IN- J9VE24-124- 095 dated 06.02.2024	17,70,000.00
19	Agilent 600 Bar HPLC – 1260 Infinity II with UV	Agilent Technologies, Agilent	Quotation Number: IN- J9VE24-124-	35,40,000.00


Skylimit Research Private Limited



Director

	detector and Autosampler • IQ/OQ included	Technologies India Pvt. Ltd. Block C, RMZ Centennial, Plot Nos. 8A, 8B, 8C & 8D, Doddanakundi Industrial Area, ITPL Road, Mahadevapura Post, Bangalore-560048	095 dated 06.02.2024	
20	Agilent ECM – XT Server to connect HPLC/LCMS and ICPMS • IQ/OQ included	Agilent Technologies, Agilent Technologies India Pvt. Ltd. Block C, RMZ Centennial, Plot Nos. 8A, 8B, 8C & 8D, Doddanakundi Industrial Area, ITPL Road, Mahadevapura Post, Bangalore-560048	Quotation Number: IN-J9VE24-124-095 dated 06.02.2024	59,00,000.00
21	Agilent 1260 Infinity II HPLC system with 800 bar pressure, Autosampler with chiller, Multicolumn compartment with thermostat and UV Detector. • PC and Printer are not included	Agilent Technologies, Agilent Technologies India Pvt. Ltd. Block C, RMZ Centennial, Plot Nos. 8A, 8B, 8C & 8D, Doddanakundi Industrial Area, ITPL Road, Mahadevapura Post, Bangalore-560048	Quotation Number: IN-J9VE24-124-095 dated 06.02.2024	2,36,00,000.00

Skyllimit Research Private Limited



Director



22	Agilent 6475 LCMSMS system • PC and Printer are included • Nitrogen Generator included	Agilent Technologies, Agilent Technologies India Pvt. Ltd. Block C, RMZ Centennial, Plot Nos. 8A, 8B, 8C & 8D, Doddanakundi Industrial Area, ITPL Road, Mahadevapura Post, Bangalore-560048	Quotation Number: IN-J9VE24-124-095 dated 06.02.2024	8,26,00,000.00
23	Supply of DAIKIN Make Ductable /Cassette Type/ Split Type Air conditioners and Installation Work	Uniaer Engineering Company, Noida	Invoice Ref no. AS/DSU/UEC/1 02/23-24 Dated :-05-02-2024,	49,30,375.00
24	Mahindra Scorpio Classic S 75 TR	Shiva Auto Cat (India) Pvt Ltd, Patparganj Industrial Area, Delhi-92	Invoice dated 02.03.2024	15,83,332.00
25	Mahindra Bolero Power Plus 86	Shiva Auto Cat (India) Pvt Ltd, Patparganj Industrial Area, Delhi-92	Invoice dated 02.03.2024	11,05,911.00
	<b>TOTAL</b>			<b>40,19,07,316.60</b>

## Manpower requirement

Human capital is likely to be the highest cost as a proportion of the budget of a CRO. Human capital costs include the cost of the existing staff spending time on, or any new team members hired, to meet the CRO objectives. It also includes fees for external consultants or agency teams, if using them. To

Skylimit Research Private Limited



Director

effectively manage 100 beds and 2 LC-MS/MS, the required personnel are detailed as follows:

**Clinical Department:**

**1. Head Clinical:**

Experience: Above 10 years

Quantity: 1 Approximate salary Rs. 25.00 lacs per annum per head

**Principal Investigator:**

Experience: Above 5 years

Quantity: 2 Approximate salary Rs. 15.00 lacs per annum per head

**Research Associate:**

Experience: Above 5 years

Quantity: 4 Approximate salary Rs. 4.00 lacs per annum per head

**Phlebotomist:**

Experience: Above 5 years

Quantity: 5 Approximate salary Rs. 2.50 lacs per annum per head

**Pharmacist:**

Experience: 2-3 years

Quantity: 2 Approximate salary Rs. 2.50 lacs per annum per head

**Trainee:**

Experience: 1-2 years

Quantity: 4 Approximate salary Rs. 2.00 lacs per annum per head

**Custodian and Recruiter:**

Experience: Above 5 years

Quantity: 2 Approximate salary Rs. 7.50 lacs per annum per head

**Total (Clinical): 20**

**Bioanalytical Department:**

**1. Head Bioanalytical:**

- Experience: Above 10 years
- Quantity: 1 Approximate salary Rs. 15.00 lacs per annum per head

**2. Team Leader:**

- Experience: Above 7 years
- Quantity: 3 Approximate salary Rs. 12.00 lacs per annum per head

**3. Research Associate:**

- Experience: Above 5 years
- Quantity: 4 Approximate salary Rs. 5.00 lacs per annum per head

**4. Trainee:**

Skylimit Research Private Limited



Director

- Experience: 1-2 years
  - Quantity: 4 Approximate salary Rs. 2.50 lacs per annum per head
5. **Custodian:**
- Experience: Above 5 years
  - Quantity: 1 Approximate salary Rs. 7.50 lacs per annum per head

**Total (Bioanalytical): 13**

**Quality Assurance:**

1. **Head Quality Assurance:**
- Experience: Above 10 years
  - Quantity: 1 Approximate salary Rs. 15.00 lacs per annum per head
2. **Clinical QA:**
- Experience: Above 7 years
  - Quantity: 1 Approximate salary Rs. 10.00 lacs per annum per head
3. **Clinical QA Associate:**
- Experience: 3-5 years
  - Quantity: 2 Approximate salary Rs. 5.00 lacs per annum per head
4. **Bioanalytical QA:**
- Experience: Above 7 years
  - Quantity: 1 Approximate salary Rs. 10.00 lacs per annum per head
5. **Bioanalytical QA Associate:**
- Experience: 3-5 years
  - Quantity: 2 Approximate salary Rs. 5.00 lacs per annum per head

**Total (Quality Assurance): 7**

**Statistical:**

1. **Statistician:**
- Experience: Above 5 years
  - Quantity: 1 Approximate salary Rs. 6.00 lacs per annum per head

**Total (Statistical): 1**

**Report Writing:**

1. **Team Leader:**
- Experience: Above 7 years
  - Quantity: 1 Approximate salary Rs. 7.50 lacs per annum per head
2. **Research Associate:**
- Experience: Above 5 years
  - Quantity: 2 Approximate salary Rs. 6.00 lacs per annum per head

**Total (Report Writing): 3**

Skylimit Research Private Limited



Director



HR:

**1. HR Manager:**


- Experience: Above 7 years
- Quantity: 1 Approximate salary Rs. 7.50 lacs per annum per head

**Overall Total: 45**

**Manpower cost/Total annual salary bill during the 1<sup>st</sup> year:**

S.No.	Designation of staff	No. of staff	Total annual salary
1	Head Clinical	1	25,00,000.00
2	Principal Investigators	2	30,00,000.00
3	Research Associates for clinical department	4	16,00,000.00
4	Phlebotomists	5	12,50,000.00
5	Pharmacists	2	5,00,000.00
6	Trainee	4	8,00,000.00
7	Custodian and Recruiter	2	15,00,000.00
8	Head Bioanalytical	1	15,00,000.00
9	Team Leader	3	36,00,000.00
10	Research Associate	4	20,00,000.00
11	Trainee	4	10,00,000.00
12	Custodian	1	7,50,000.00
13	Clinical QA Associate	2	10,00,000.00
14	Bioanalytical QA	1	10,00,000.00
15	Bioanalytical QA Associate	2	10,00,000.00
16	Statistician	1	6,00,000.00
17	Report Writing team leader	1	7,50,000.00
18	Report Writing Research Associate	2	12,00,000.00
19	HR Manager	1	7,50,000.00
20	Head Quality Assurance	1	15,00,000.00
21	Clinical QA	1	10,00,000.00
	<b>Total</b>	<b>45</b>	<b>2,88,00,000.00</b>

Skyllmit Research Private Limited



Director

### **Expenses on Regulatory approvals incurred during 1<sup>st</sup> year:**

The regulatory landscape in the pharmaceutical industry is complex and constantly continuously evolving. CROs need to navigate a multitude of regulatory requirements imposed by different regulatory bodies, such as the U.S. Food and Drug Administration (FDA), the European medicines Agency (EMA), and other national regulatory authorities. Regulatory requirements and approval processes can vary significantly across different regions and countries. CROs operating globally must navigate these regional variations and adapt their strategies accordingly. Each region may have unique documentation requirements, local safety reporting obligations, and specific regulatory approval timelines.

The clinical development is a most regulated segment of drug development process because it deals with humans. ICH-GCP norms are globally followed while conducting the clinical trials to ensure the safety, rights and wellbeing of the clinical trial participants. In addition, country specific applicable rules and regulations are also applicable of the pharmaceutical companies conducting the clinical trials.

Regulatory agencies often require extensive documentation, data analysis, and review processes before granting approval for clinical trials or new drug applications. These approval delays can have substantial financial implications for CROs and sponsors, as they lead to extended timelines, increased costs, and potential loss of market opportunities. This has paved a way for the pharmaceutical companies to move to other attractive destinations in Asia Pacific regions like China and Australia.

Regulatory timelines for clinical trials in India are non-starter for foreign companies exploring India as destination for clinical trial in recent past. Delays in the approval process for clinical trials and drug development have significantly impacted the CRO Industry. Central Drugs Standards Control Organisation (CDSCO), the top most regulator of clinical trials in India, has been

Skyllmit Research Private Limited



Director



at loggerheads with Indian pharma and CROs over the unprecedented delays in approval of clinical trials in past.

Regulatory reforms post 2013 and the introduction of New Drugs and Clinical Trial Rules of 2019 have partially streamlined the approval processes, reduced the timelines by 30-40%, and introduced several exemptions and provisions to improve the overall efficiency of conducting clinical trials. In addition, some other initiatives like Audio Visual consenting of patients, Ethics committee registration, new compensation law and robust scrutiny system for the Clinical Trial applications have been implemented. These are aimed at streamlining the processes and making the systems transparent.

The below mentioned table represents some of the regulatory approvals, registration, accretions and the certifications the different kind of CROs need to maintain in order to be complaint to the applicable quality and regulatory requirements.

Service Area	Applicable Regulatory Approvals, Accreditations & Certifications
Discovery CROs	GLP certification by National GLP Compliance Monitoring Authority, DST, Gol Department of scientific and industrial research (DSIR) Certification GMP certification by state FDA ISO 9001:2015 (Quality Management System) ISO 17025:2017 (Laboratory Management System) Testing and Calibration Labs
Pre-Clinical CROs	GLP certification by National GLP Compliance Monitoring Authority, DST, Gol, India Committee for the Purpose of Control & Supervision of Experiments on Animals (CPCSEA) AAALAC accreditation. ISO 9001:2015 (Quality Management System)
Bioequivalence Bioavailability CROs	BE center approval from Central Drug Standards Control Organization (CDSCO), India Independent Ethics committee (IEC) registration with Central Drug Standards

Skyllmit Research Private Limited



Director



	Control Organization (CDSCO), India Foreign Regulatory Approvals like USFDA, EMEA, UKMHRA, ANVISA, TGA etc. NABL certification as per ISO 15189:2016 or College of American Pathologists (CAP) certification for Safety Testing Laboratory GLP compliance of Bioanalytical Section of Bioequivalence centre ICH-GCP compliance ISO 9001:2015 (Quality Management System)
<b>Clinical Trials (Phase I-IV) CROs</b>	CRO registration with CDSCO is not mandatory yet. CDSCO is going to make it mandatory very soon. Institutional Ethics committee (IEC) or Institution Review Board registration with Central Drug Standards Control Organization (CDSCO), India ICH-GCP compliance ISO 9001:2015 (Quality Management System)

The company will approach the respective Regulating Authorities for the requisite Approvals, Accreditations & Certifications after the CRO is fully established consisting of the complete infra setup and positioning of the requisite staff of the CRO, which will take 06 months' time and another 06 months' time will be spent in the process of getting the Approvals, Accreditations & Certifications from the respective Regulating Authorities and the company will have to spend/provide for significant amount of funds to the tune of Rs. 1.00 crores for obtaining the various Applicable Regulatory Approvals, Accreditations & Certifications from the concerned authorities.

#### **Lease Rentals during the Implementation period:**

The Company has executed lease agreement on 29.01.2024 the premises situated at Plot no. 28, Sector 155, Phase II, Noida, which is a 04 story building constructed on a plot area 1000 square meters and the entire leasable area is 32000 square feet which is sufficient for the setting up of the CRO. The monthly lease rent is Rs. 6,40,000.00 and the initial lease period is for 5 years with 5% annual increase in rent after expiry of 12 months of lease period and the lease agreement shall be automatically renewed for next 05 years after the expiry of the agreement as per the agreed terms. At this rate the company will have to pay Rs. 76,80,000.00 to the lessor during the 1st year. In addition to it,

Skylimit Research Private Limited



Director

the company has deposited a sum of Rs. 12,80,000.00 to the Lessor as Interest Free Security Deposit as per the terms of the lease. As such the company has incurred/will incur total pre-operative expenses of Rs. 89,60,000.00 under this head.

**Interest on term loan during the Implementation period:**

The company will have to pay monthly interest approximately @ 10% pa during the 1st year which will be covered in the Implementation stage and on the term loan limit of Rs. 30.00 crores, the approximate interest amount for the 1st year will be around Rs. 2.00 crores.

**General miscellaneous/operational expenses of the CRO during the 1<sup>st</sup> year:**

The general operational expenses viz electricity, municipal taxes, housekeeping, watch & ward, conveyance charges, general maintenance, and other miscellaneous expenses to the tune of Rs. 1.00 crores have been stipulated during the Implementation period.

**Project Cost**

The total project cost of the CRO is the fixed cost incurred for purchase of the equipment's, plant/machineries, creation of infrastructure and also the intangible assets being the preliminary expenses being the manpower cost, expenses for getting the regulatory approvals, lease rentals, repayment of interest/other financials expenses on term loan/credit facilities, other general expenses to be incurred during the stipulated implementation period s under:

**Summary of the cost of project and means of finance**

**TOTAL PROJECT COST:**

(Amount Rs. in lacs)

Skyllmit Research Private Limited



Director

Particulars	Total (Amount)
Plant & Machinery at the prices on quotations held with all expenses on taxes, freight, installation, and insurance	40,19,07,316.60
Preliminary/Pre-operative Expenses on Manpower cost/ Regulatory approvals/Lease Rentals/ Interest on term loan/ General miscellaneous/operational expenses of the CRO during Implementation period	3,88,80,000.00
<b>Total</b>	<b>44,07,87,326.60</b>

### **Means of Finance:**

(Rs. in lacs)

Particulars	Total Cost	Margin	Promoter's share	Term Loan
Plant Machinery, Equipment's and misc assets.	40,19,07,316.60	25%	10,19,07,316.60	30,00,00,000.00
Total Preliminary/Pre-operative Expenses during Implementation period	3,88,80,000.00	100%	3,88,80,000.00	0.00
	44,07,87,326.60		14,07,87,326.60	30,00,00,000.00
<b>Term Loan</b>	<b>Rs. 3000.00 lacs</b>			

Skylimit Research Private Limited



Director



**Permissible Term Loan: Rs. 3000.00 lacs**

DER of the unit is proposed at 2.14 as at 31.03.2024 which is well within acceptable limits of the bank. Average DSCR is projected to be at 1.73 as on 31.03.2025 and 1.80 as on 31.03.2026 which is reasonable.

**Breakeven point**

According to the proposed plan for the Clinical Research Organization setup, a tentative profit margin of 35% is anticipated. The company is expected to book net profit in the 1st full year of operations.

**FACILITIES AND INFRASTRUCTURE**

M/S Skylimit Research Private Limited will have state-of-the-art facilities and infrastructure to facilitate quality execution of studies. The main components of infrastructure at M/S Skylimit Research Private Limited are well equipped Clinical, Bio-analytical and In-vitro study setup. We have state-of-the-art equipment, regulatory compliant software, hardware and secured networks.

M/S Skylimit Research Private Limited will have a well-designed, custom-built, compliant facility to conduct various activities of Clinical Research in Noida. It will spread over a total floor area of 32,000 sq.ft., which will cover the Clinical Units, Analytical Laboratory area, Volunteer screening area, Volunteer Information centers and external archives.


**Clinical Facilities:**

All the clinical activities will be conducted in compliance with Global Regulatory Standards and the clinical unit meets world-class specifications.

**Noida Clinical Facility:**

- Facility having more than 32,000 sq. ft. of carpet area
- Clinical unit with 100 beds facilitating simultaneous conduction of multiple studies resulting in quick turnaround time

**Skylimit Research Private Limited**



**Director**

- Ease of conducting mix population studies with separate housing areas for Male and Female Subjects
- Clinical pathology lab accredited by the College of American Pathologists (CAP) and National Accreditation Board for Testing and Calibration Laboratories (NABL) equipped to carry out tests for biochemistry, haematology, urine chemistry and serology as per study requirements
- The clinical facility will be approved by DCGI (INDIA) and will be fully compliant with ICH GCP and other International Regulations like USFDA, WHO, UK MHRA, TGA (Australia), Canada, etc



Indicative photograph of the proposed CRO-1

Skylimit Research Private Limited

Director





Indicative photograph of the proposed CRO-2

## BIO-ANALYTICAL FACILITY:

We will have a fully GLP-compliant analytical facility with state-of-the-art laboratories spread over 8,000 sq ft and managed by highly skilled and experienced scientific professionals and support personnel.

This team is competent to develop and validate a minimum of 4-6 methods every month. Thus, we have a faster turnaround time for developing the molecule as well as testing it.

### State-of-the-art laboratory facilities for bio-analysis:

- Latest Instrumentation and technology to ensure project completion with quick-turnaround time
- We will offer – Electronic documentation (paperless) and are working on Scientific Data Management System (SDMS), Laboratory Information Management System (LIMS) and eLab (electronic Lab) notebook
- Sample storage in controlled and limited access Deep freezer room with power back up and 24\*7 temperature Monitoring and alarm system

Skyllimit Research Private Limited

*Carey*

Director



- Access controlled entry and exit facility
- Separate sample processing laboratory
- Validated and regulatory compliant software at M/S Skylimit Research Private Limited Research ensures movement of data from the analytical lab to documentation within a CFR Part 11 compliant environment
- Major equipment under annual maintenance contracts to minimize down time



Indicative photograph of the proposed CRO-3

### IN-VITRO STUDY SETUP:

M/S Skylimit Research Private Limited Research, a leader in In-vitro Release Testing (IVRT) and In-vitro Permeation Testing (IVPT) analytical method development, validation, and testing services, has continued to meet the fast-growing demand for these types of topical and transdermal drug analytical services with the most up to date regulatory requirement.


Through the use of appropriately selected In Vitro and In Vivo surrogate tests, we can accomplish the assessment of the BE of topical drug products. For most products IVRT, IVPT, and additional testing would be essential to establish BE along with Q1/Q2 testing.

Skylimit Research Private Limited

*Karan*

Director





Indicative photograph of the proposed CRO-4



Indicative photograph of the proposed CRO-5

Skylimit Research Private Limited

*Karan*

Director

ONE STOP SOLUTION FOR STUDIES ON TOPICAL, OPHTHALMIC  
AND PARENTERAL PRODUCTS:

### **IN-VITRO STUDIES**

INDEPENDENT SETUP TO CONDUCT IN-VITRO STUDIES (IVRT/IVPT)

EQUIPPED WITH 11 FRANZ DIFFUSION CELL CONSOLES OF LOGAN WITH AUTO-  
SAMPLER

120 CELLS FOR MULTIPLE STUDY CONDUCT

+ 20 – IN-VITRO RELEASE TESTING (IVRT) STUDIES COMPLETED

+ 10 – IN-VITRO SKIN PERMEATION TESTING (IVPT) STUDIES COMPLETED

### **BCS BIOWAIVER STUDIES**

SETUP TO CONDUCT BCS BIOWAIVER STUDIES

20 MODEL DRUG METHOD VALIDATED

7 STUDIES SUBMITTED FOR REGULATORY APPROVALS, 2 STUDIES ALREADY  
APPROVED

### **IN-VITRO FEEDING TUBE STUDIES**

SEPARATE SET-UP TO CONDUCT IN VITRO FEEDING TUBE STUDIES

EXPERIENCE WITH FORMULATIONS OF CAPSULE PELLETS AND ORAL  
SUSPENSIONS

#### **SALIENT POINTS:**

- Independent regulatory-compliant facility for in-vitro dermal studies
- Expanded the In-vitro facility by adding 11 Franz diffusion cell consoles of Logan with auto-sampler
- 120 cells for multiple study conduct
- In vivo skin permeation – Dermal Microdialysis complete setup
- In vivo skin permeation – Tape stripping complete setup

Skyllmit Research Private Limited



Director



- Vasoconstrictor assay (Skin Blanching) using Chromameter

**Salient Features of Facilities:**

- Clinical Research facility with attached Analytical, Support, and Ancillary Functions
- State-of-the-art Analytical, In-vitro study setup, and NABL Accredited clinical Lab
- Designated to International safety standard
- Access Control to all crucial labs to support confidentiality
- Ample storage facility for retaining samples at -20°C and -70°C
- Pool of latest and highly sensitive mass spectrophotometers and allied instruments
- Regulatory compliant archiving facility spread over 5,000 sq ft
- Systems with validated software that is CFR 21 Part 11 compliant

**M/S Skylimit Research Private Limited: Regulatory Services**

**Included But will not be Limited To:**

- To achieve the regulatory goal, we can suggest a concrete regulatory strategy to give you a competitive advantage
- Provide detailed feasibility before study execution to get real-time information and expected timelines.
- Preparation & submission of regulatory documents for obtaining:
- Approval to conduct a clinical trial in India
- Approval to import Investigational Products
- Central Bureau of Narcotics (CBN) and State FDA permit to import Narcotic and Psychotropic substances
- Liaising and Obtaining registration documents in the interest of clients
- Continuous follow-up post submission with regulatory authorities
- Safety reporting

**Skylimit Research Private Limited**



**Director**

- Preparation of regulatory submissions in CTD and eCTD format
- Preparation of summaries required for generic submission
- Executing regulatory submission
- Responding to the health authorities' queries during the approval phases of the product

### **Future projections of the company- Key financials**

The key financial projections of the company for next 03 years are as under:

Amount Rs. in crores

Particulars	31.03.25	31.03.26	31.03.27	31.03.28	31.03.29	31.03.30	31.03.31	31.03.32	31.03.33
	Projected	Projected	Projected	Projected	Projected	Projected	Projected	Projected	Projected
Gross Revenue	4.00	22.00	35.00	42.00	50.00	59.50	66.35	79.62	95.55
% wise rise/fall in total sales	NA	450.00	59.09	20.00	19.04	19.00	11.51	20.00	20.00
PBDIT	1.85	8.30	10.15	11.90	11.55	12.20	13.10	19.99	30.64
PBT	0.55	1.30	3.45	5.50	5.45	6.60	8.00	15.29	26.34
PAT	0.41	0.98	2.58	4.12	4.09	4.95	6.00	11.47	19.75
Cash Accruals	1.41	4.97	6.58	8.12	8.09	8.95	10.00	15.47	23.75
Paid up capital	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00
Tangible Net worth	10.41	10.97	12.59	14.12	14.08	14.95	16.00	21.47	29.75
Unsecured loans by promoters/relatives	2.00	4.00	2.00	1.00	0.00	0.00	0.00	0.00	0.00
Current Ratio	1.57	1.33	1.59	1.15	1.28	1.17	1.48	2.22	2.38
NWC	1.98	1.20	2.48	0.69	1.32	0.85	2.57	8.70	13.65
DSCR	1.73	1.80	2.05	2.71	2.70	2.98	3.31	5.06	7.71
Average DSCR	2.20								

**Justification for the consistent growth in performance:**

Skylimit Research Private Limited



Director

**1. Revenues:** The company is expected to start commercial operations in next 06 months after the establishment of full set up of the CRO and obtaining the mandatory approvals from the respective agencies and based on the proposed Clinical Research Organization setup and the above assumptions, the company expects to garner total 50 studies (25 Pilot and 25 Pivotal) in 1st year of the operations and the number of studies are expected to increase to 100 and 150 with 50% share of Pilot and Pivotal studies in the 2nd and 3rd year of operations.

The Yearly cost comparisons for actual study subject costs vis-à-vis vendor industry costs and expected revenues are outlined below for 50 studies (25 Pilot and 25 Pivotal) in a year:

Sr. No.	Content	Actual Study Subject Cost (INR)	Vendor Cost /Revenues expected (INR)
<b>Clinical</b>			
1	Clinical per subject cost	17,000	24,000
2	Study considering 30 subjects	5,10,000	7,20,000
3	Clinical test	1,000	1,500
4	Clinical test considering 30 subjects	30,000	45,000
<b>Total Clinical</b>	<b>Total Clinical Study cost for 30 subjects</b>	<b>5,40,000</b>	<b>7,65,000</b>
<b>Bioanalytical</b>			
5	Average cost for a single bioanalytical sample	500	800
6	Average cost for a single subject analysis for 50 tests	25,000	40,000

Skylimit Research Private Limited



Director



7	Average cost for a 30 subject analysis for 50 tests	7,50,000	12,00,000
8	Approximate cost for 25 Pilot studies (covering average number of 30 subjects in each Pilot study) in a year	5,40,000 X 25 = Rs. 1,35,00,000 <b>Plus</b> 7,50,000X 25 = Rs. Rs. 1,87,50,000 <b>Sub-total = Rs. 3,22,50,000</b>	7,65,000 X 25 = Rs. 1,91,25,000 <b>Plus</b> 12,00,000X 25 = Rs. Rs. 3,00,00,000 <b>Sub-total = Rs. 4,91,25,000</b>
9	Approximate cost for 25 Pivotal studies (covering average number of 60 subjects in each Pivotal study) in a year	5,40,000 X 2 X 25 = Rs. 2,70,00,000 <b>Plus</b> 7,50,000X 2 X 25 = Rs. 3,75,00,000 <b>Sub-total = Rs. 6,45,00,000</b>	7,65,000 X 2 X 25 = Rs. 3,82,50,000 <b>Plus</b> 12,00,000X 2 X 25 = Rs. 6,00,00,000 <b>Sub-total = Rs. 9,82,50,000</b>
10	Other Miscellaneous cost for 25 Pilot and 25 Pivotal studies (covering average number of 60 subjects in each Pivotal study) in a year @ 65000/- per study	<b>Rs. 32,50,000</b>	<b>Rs. 32,50,000</b>
<b>11.Overall Cost</b>	Approximate cost for 50 studies (25 Pilot and 25 Pivotal) in a year	<b>10,00,00,000</b>	<b>15,06,25,000</b>

The company expects to achieve total revenue generation of Rs. 4.00 crores in the 1<sup>st</sup> year of operations i.e. FY 2024-25 which is expected to increase to Rs. 22.00 crores, Rs. 35.00 crores and Rs. 42.00 crores during the FY 2025-26, FY 2026-27 & FY 2027-28 respectively which is a reasonable estimation.

**2.Profitability:** The company will be able to turn into net/cash profit in the 1<sup>st</sup> year of working with net profit(after tax) Rs. 0.41 crores in the FY 2024-25 and the company

Skyllimit Research Private Limited

*Karan*

Director

expects increase in net profit(after tax) to Rs. 0.97 crores in year 2025-26 which is expected to increase to Rs. 2.58 crores in year 2026-27 which is quite reasonable and achievable.

**3.Net Worth:** The Company has authorized capital of Rs. 10.00 lacs which is being enhanced to Rs. 12.00 crores and the paid up capital is being enhanced to Rs. 10.00 crores by the end of FY 2023-24. With the retention of the net profits in the company, the net worth is projected to increase to Rs. 10.41 crores as on 31.03.2025, Rs. 10.98 crores as on 31.03.2026 and Rs. 12.98 crores as on 31.03.2027 as per projected financial data attached which is quite reasonable and achievable considering the strong prospectives of the sector.

**4. Current Ratio:** The current ratio is expected to be 1.57 as on 31.03.2025 and it is expected to remain at 1.33 and 1.59 as at 31.03.2026 and 31.03.2027 respectively which is reasonable and acceptable.

**5. NWC:** The NWC of the company is expected to be Rs. 1.90 crores as on 31.03.2024 and it is expected to remain at Rs. 1.98 crores, Rs. 1.21 crores and Rs. 2.48 crores as at 31.03.2025, 31.03.2026 and 31.03.2027 respectively which is reasonable and acceptable.

**6. DSCR:** The DSCR is expected to be 1.73 as on 31.03.2024 which is further expected to increase to 1.80, 2.05 and 2.71 as on 31.03.2025, 31.03.2026 and 31.03.2027 respectively due to increased profitability and the average DSCR is expected to remain at 2.20 which gives sustainable repaying capability of the company against long term advances.

**Properties/Collateral proposed for equitable mortgage for the Term Loan/Credit facilities at Punjab National Bank:**

(Amt. Rs in lacs)			
Security Description	Ownership	Present market value	Fresh or existing
Leasehold flat no. DC-3-201, area measuring 369.39 sq mtres situated at Jade Apartment, Delcourt, Jaypee Greens, Greater Noida	Sri Arjun Singh Rawat & Smt Poonam Rawat	500.00	Extension of existing collateral in credit facilities to M/S Rawat Associates.
Residential plot no., D-115, area 288 sq mtres situated at	Sri Arjun Singh Rawat	100.00	Extension of existing collateral in

Skyllmit Research Private Limited



Director

Yamunapuram, Bulandshahar,UP			credit facilities to M/S Rawat Associates.
Residential plot no., D-116, area 288 sq mtres situated at Yamunapuram, Bulandshahar,UP	Smt Poonam Rawat	100.00	Extension of existing collateral in credit facilities to M/S Rawat Associates.
Residential double storey house no., MIG-701, area 121.89 sq mtres situated at Avantinagar, DM Road, Avas Vikas, Bulandshahar,UP	Sri Arjun Singh Rawat	150.00	Extension of existing collateral in credit facilities to M/S Rawat Associates.
Property known as "SWARIS WADO" admeasuring 950 Sq.Mtres under survey no. 79, Sub-division no. 9, Vill. Marna, Bardez Taluka, Disstt. North Goa	50% share of the property is owned by Mr. Ashish Vijaysinh Prabhugaokar & Mrs. Vijaya Prabhugaokar and 50% share owned by Mr. Yash Pratap Singh	1200.00	Fresh
<b>Total</b>		<b>2050.00</b>	

**Personal guarantees:**

Skyllimit Research Private Limited



Director




S. No.	Guarantors' name	Address and contact number	PAN, Aadhar and other details
1	Karan Pratap Rawat S/O Sri Arjun Singh Rawat	Villa no. V-2/9, Block G, Jaypee Greens, Greater Noida, UP	PAN No. GXWPS7371F  Aadhar No. 806698463827
2	Sandeepika Sharma D/O Sanjay Sharma,	380, Kather Bypass Road, Solan, Himanchal Pradesh-173213	PAN No. LXRPS6218R  Aadhar No. 714667948713
3	Sri Arjun Singh Rawat	Villa no. V-2/9, Block G, Jaypee Greens, Greater Noida, UP	PAN No. AFLPR1341B Aadhar No. 504182619327
4	Smt Poonam Rawat	Villa no. V-2/9, Block G, Jaypee Greens, Greater Noida, UP	PAN No. AYNPS6522L Aadhar No. 241450116454
5	Mr. Ashish Vijaysinh Prabhugaokar	32/18, op Floor, Near Cambridge School, Srinivaspuri, South Delhi, Delhi-110065	PAN No. CBHPP3032M, Aadhar No. 831916202775
6	Mrs. Vijaya Prabhugaokar	32/18, op Floor, Near Cambridge School, Srinivaspuri, South Delhi, Delhi-110065	PAN No. AIXPP3353L, Aadhar No. 402965889101
7	Mr. Yash Pratap Singh	Villa no. V-2/9, Block G, Jaypee Greens, Greater Noida, UP	PAN No. MSCPS9247R Aadhar No. 226536725538

We attach herewith copies of the following documents/copies:

1. CMA data of the company for the FY 2023-24 to 2032-33
2. GST Registration certificate of the company
3. PAN/Aadhar of Sri Karan Pratap Rawat.
4. PAN/Aadhar of Ms. Sandeepika Sharma
5. PAN/Aadhar of Smt. Poonam Rawat.
6. PAN/Aadhar of Sri Arjun Singh Rawat.
7. PAN/Aadhar of Sri Yash Pratap Singh
8. PAN/Aadhar of Sri Ashish Vijaysinh Prabhugaokar
9. PAN/Aadhar of Smt. Vijaya Prabhugaokar
10. ITRs of Sri Karan Pratap Rawat for the AY 2023-24.

Skylimit Research Private Limited



Director

11. ITRs of Ms. Sandeepika Sharma for the AY 2023-24.
12. ITRs of Smt. Poonam Rawat for the AY 2023-24.
13. ITRs of Sri Arjun Singh Rawat for the AY 2023-24.
14. ITRs of Sri Yash Pratap Singh for the AY 2023-24.
15. ITRs of Sri Ashish Vijaysinh Prabhugaokar for the AY 2023-24.
16. ITRs of Smt. Vijaya Prabhugaokar for the AY 2023-24.
17. Memorandum & Article of Association of the Company
18. UDYAM certificate of the Company
19. Lease deed of the company registered at bahi no. 1, Sl. No. 520 at Sub-Registry, Noida on 29.-1.2024
20. Copy of Invoice No.- CBS/ srpl/2024/01 dated 12.01.2024 of Care Biosystems India Pvt. Ltd Mumbai for supply of Haier make Freezer, 230V/50 Hz
21. Copy of Invoice No.- IN-J9AB1S-124- 10522553 dated 12.01.2024 of Agilent Technologies I Pvt Ltd for supply of 600 bar HPLC with DAD
22. Copy of Invoice No.- IN-J9AB1S-124- 10522553 dated 12.01.2024 of Agilent Technologies I Pvt Ltd for supply of 600 bar HPLC with UV detector
23. Copy of Invoice No.- IN-J9AB1S-124- 10522553 dated 12.01.2024 of Agilent Technologies I Pvt Ltd for supply of FLD single wavelength
24. Copy of Invoice No.- SCIEX-Delhi/HT/Skylimit/174282/24 dated 12.01.2024 of SCIEX India Pvt. Limited for supply of SCIEX Triple Quad 4500 System Upgradeable to QTRAP
25. Copy of Invoice No.- SCIEX-Delhi/HT/Skylimit/174281/24 dated 12.01.2024 of SCIEX India Pvt. Limited for supply of SCIEX Triple Quad 5500+ System QTRAP Activated- Enhanced high performance triple quadrupole LC-MS/MS mass spectrometer
26. Copy of Invoice No.- SBI/LGN/SKY/91324/186/2023-24 dated 11.01.2024 of SANGUINE BIO INSTRUMENTS, Hyderabad for supply of Logan Water Jacketed Automated Transdermal Diffusion Cell System(24Cell System)
27. Copy of Invoice No.- BSL/BCS/23-24/308 dated 10.01.2024 of BLUE COOL SOLUTIONS, MUMBAI for Supply & Installation of Walk in Freezer Room with Ante Room
28. Copy of Invoice Email dated 16.01.2024 of Takahe Analytical Instruments, Navi Mumbai for Supply of Bio-eVap DP Nitrogen Evaporator(Dual Press 144 Position)
29. Copy of Invoice No.- S000478 Dated 10.01.2024 of Eppendorf India Private Limited Jasola Vihar, New Delhi for Supply of 5702 R with A-4-38 rotor incl. adaptor for 13/16 mm blood collection tubes
30. Copy of Invoice No.- Email dated 16.01.2024 of Eppendorf India Private Limited Jasola Vihar, New Delhi for Supply of Micropipettes ( Volume range 10-100 ul, 20-200 ul , 100-1000 ul and 500-5000 ul ) each Volume range
31. Copy of Invoice No.- Email dated 16.01.2024 of Eppendorf India Private Limited Jasola Vihar, New Delhi for Supply of Multipette M4 Starter kit , 1- channel, incl. Combitips advance rack, Combitips advance assortment pack
32. Copy of Invoice No.- APC/MRC/OFFER/ 23-24/752 dated 03.01.2024 of ADHARSHILA POWER CORPORATION G- 200, Sector-63, Noida for Techno-Commercial Offer for MEP & Interior work

Skyllimit Research Private Limited



Director




33. Copy of Invoice No.- of Kirloskar for supply of Kirloskar 125 KVA water cooled Genset three phase
34. Copy of Invoice No.- SB0123/2024/240124 dated 24.01.2024 of SB Bio Chem for supply of Entris II Analytical balance and Cubis II Micro Analytical balance
35. Copy of Invoice No.- IN-J9VE24-124-095 dated 06.02.2024 of Agilent Technologies, Agilent Technologies India Pvt. Ltd. for supply of Agilent ICPMS – 7850 • PC and Printer including accessories
36. Copy of Invoice No.- IN-J9VE24-124-095 dated 06.02.2024 of Agilent Technologies India Pvt. Ltd. for supply of Non Agilent Product Microwave Digestion system
37. Copy of Invoice No.- IN-J9VE24-124-095 dated 06.02.2024 of Agilent Technologies India Pvt. Ltd. for supply of Agilent 600 Bar HPLC – 1260 Infinity II with UV detector and Autosampler
38. Copy of Invoice No.- IN-J9VE24-124-095 dated 06.02.2024 of Agilent Technologies India Pvt. Ltd. for supply of Agilent ECM – XT Server to connect HPLC/LCMS and ICPMS
39. Copy of Invoice No.- IN-J9VE24-124-095 dated 06.02.2024 of Agilent Technologies India Pvt. Ltd. for supply of Agilent 1260 Infinity II HPLC system with 800 bar pressure, Autosampler with chiller, Multicolumn compartment with thermostat and UV Detector
40. Copy of Invoice No.- IN-J9VE24-124-095 dated 06.02.2024 of Agilent Technologies India Pvt. Ltd. for supply of Agilent 6475 LCMSMS system PC and Printer included,
41. Copy of Invoice No.- AS/DSU/UEC/102/23-24 Dated :-05-02-2024 of Uniaer Engineering Company, Noida for supply of DAIKIN Make Ductable /Cassette Type/ Split Type
42. Copy of Invoice dated 02.03.2024 of Shiva Auto Cat (India) Pvt Ltd, Patparganj Industrial Area, Delhi-92 for purchase of Mahindra Scorpio Classic S 75 TR
43. Copy of Invoice dated 02.03.2024 of Shiva Auto Cat (India) Pvt Ltd, Patparganj Industrial Area, Delhi-92 for purchase of Mahindra Bolero Power Plus 86

Thanks,

Yours faithfully

Skyllimit Research Private Limited

  
Karan Pratap Rawat  
Director  
Director